Drug Price Trends for ABILIFY MAINTENA ER

Average Pharmacy Cost for ABILIFY MAINTENA ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ABILIFY MAINTENA ER 300 MG SYR	59148-0045-80	2138.88516	EACH	2026-05-20
ABILIFY MAINTENA ER 300 MG VL	59148-0018-71	2144.54421	EACH	2026-05-20
ABILIFY MAINTENA ER 400 MG VL	59148-0019-71	2859.50915	EACH	2026-05-20
ABILIFY MAINTENA ER 400 MG VL	59148-0245-12	2859.50915	EACH	2026-05-20
ABILIFY MAINTENA ER 300 MG VL	59148-0018-70	2144.54421	EACH	2026-05-20
ABILIFY MAINTENA ER 400 MG SYR	59148-0072-80	2856.67011	EACH	2026-05-20
ABILIFY MAINTENA ER 300 MG VL	59148-0232-12	2144.54421	EACH	2026-05-20

Market Analysis and Price Projections for ABILIFY MAINTENA ER

Last updated: February 20, 2026

What is ABILIFY MAINTENA ER?

ABILIFY MAINTENA ER (aripiprazole lauroxil) is a long-acting injectable antipsychotic used primarily for schizophrenia maintenance therapy. Approved by the FDA in 2015, it offers monthly dosing, which improves adherence compared to oral formulations.

Market Size and Growth

Current Market Landscape

• The global schizophrenia drug market was valued at approximately $4.2 billion in 2022.
• The U.S. accounts for roughly 70% of sales, reflecting high prescription rates and healthcare access.
• ABILIFY MAINTENA ER holds an estimated 10-15% share within long-acting injectable (LAI) antipsychotics, equating to roughly $420 million to $630 million in U.S. sales for 2022.

Growth Drivers

• Increasing recognition of adherence issues with oral medications.
• Growing diagnosis rates: approximately 1 in 100 people globally diagnosed with schizophrenia.
• Expansion into emerging markets with rising mental health awareness.
• Phase 4 clinical studies and post-marketing data highlight the drug's safety and efficacy, supporting continued adoption.

Competition and Market Share Dynamics

• Main competitors include:

  • Risperdal Consta (risperidone)
  • Invega Sustenna and Invega Trinza (paliperidone palmitate)
  • Haldol Decanoate (haloperidol)

• ABILIFY MAINTENA ER benefits from a favorable profile: once-monthly dosing, lower weight gain risk, and less sedation compared to some competitors.

Regulatory and Reimbursement Environment

• The drug has full FDA approval; insurance coverage in major markets is broad.
• In the U.S., inclusion on major formularies like Express Scripts, CVS, and Aetna supports physician prescribing patterns.
• Cost considerations influence treatment choice; listing prices impact patient access.

Price Components and Cost Projections

Current Pricing

• Wholesale acquisition cost (WAC): approximately $2,100 per month (per 2022 data).
• Average retail price: around $2,400 to $2,600 per month.
• Insurance coverage reduces patient out-of-pocket costs to approximately $250-$300 monthly, depending on deductibles and copays.

Projected Price Trends (2023-2027)

Year	Average Monthly Price	Expected Change	Rationale
2023	$2,500	Stable	Market competition and inflation adjustments.
2024	$2,550	+2%	Slight price increase due to manufacturing cost inflation.
2025	$2,600	+2%	Continued inflation, potential new formulary negotiations.
2026	$2,650	+2%	Market stabilization, minor adjustments.
2027	$2,700	+2%	Consistent with prior trends.

Price Sensitivity Factors

• Patent expirations or biosimilar entries could lower costs.
• Expanded use in other psychiatric indications, such as bipolar disorder, could expand market size.
• Reimbursement policies and payer negotiations could influence net prices.

Market Expansion Opportunities

• Growing elderly population with schizophrenia.
• Use in first-episode psychosis, although off-label.
• Potential development of longer-acting formulations (e.g., 3-month injections) could command premium pricing.

Risks to Price Projections

• Market entry of biosimilars or generic formulations post-patent expiry.
• Regulatory changes impacting reimbursement.
• Payer pressure to reduce costs may lead to discounts or formulary restrictions.

Summary

The current U.S. market for ABILIFY MAINTENA ER hovers around $420 million to $630 million annually, with steady growth driven by adherence benefits and increasing diagnoses. Wholesale prices are expected to grow modestly at approximately 2% annually until 2027, influenced by market competition, reimbursement policies, and potential formulation innovations.

Key Takeaways

• ABILIFY MAINTENA ER commands a retail price averaging $2,500/month in 2023.
• The market is projected to grow at 2% annually through 2027.
• Competition from other LAI antipsychotics remains significant.
• Market expansion relies on new indications and formulation improvements.
• Price sensitivity lies mainly in patent status and payer negotiations.

FAQs

1. What is the primary competitive advantage of ABILIFY MAINTENA ER?
   Its monthly dosing schedule and favorable side effect profile differentiate it from some competitors.

2. What is the typical patient out-of-pocket cost?
   Approximately $250-$300 monthly, depending on insurance coverage.

3. How might patent expirations affect prices?
   Loss of patent exclusivity could lead to biosimilar or generic competition, driving prices down.

4. Are there plans for longer-acting formulations?
   Regulatory development of 2- or 3-month injection options is ongoing or planned for future release.

5. What factors could accelerate market growth?
   Broader approval for additional indications, increased diagnosis rates, and expanded formulary access.

---

References

1. MarketsandMarkets. (2022). Schizophrenia therapeutics market growth report.
2. IQVIA. (2022). Prescription drug sales data.
3. U.S. Food and Drug Administration (FDA). (2015). Approval documentation for ABILIFY MAINTENA ER.
4. Drug Price Directory. (2022). Wholesale acquisition costs and retail pricing data.
5. Health Affairs. (2021). Reimbursement policies and psychotropic drug coverage studies.